Zhejiang Orient Gene Biotech Co., Ltd. (688298.SS)

CNY 29.1

(-2.68%)

Market Cap (In CNY)

5.62 Billion

Revenue (In CNY)

805.08 Million

Net Income (In CNY)

-397.58 Million

Avg. Volume

1.4 Million

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
24.4-41.49
PE
-
EPS
-
Beta Value
1.691
ISIN
CNE100003RM8
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Devices
CEO
Mr. Xiaoliang Fang
Employee Count
-
Website
https://www.orientgene.com
Ipo Date
2020-02-05
Details
Zhejiang Orient Gene Biotech Co., Ltd. researches and develops, produces, and sells colloidal gold tests, urinalysis strips, raw materials, instruments, and molecular diagnosis products primarily in China. Its products include genetic diagnosis products; colloidal gold rapid diagnostic tests for drugs of abuse, infectious diseases, fertility, cardiac and tumor markers, and autoimmunity; dry chemical strips; bio-liquid diagnostic kits; clinical test instruments; POCT time-resolved fluor immunoassay test kits; raw materials; etc. The company also exports its products to North and South America, Europe, South Asia, Southeast Asia, the Middle East, Africa, Russia, and Australia. Zhejiang Orient Gene Biotech Co., Ltd. was founded in 2005 and is based in Huzhou, China.

More Stocks